Sienna Cancer Diagnostics
Follow
Get notifications in MyBN when activity occurs.
Melbourne-based Sienna Cancer Diagnostics is a public listed company with global operations. Head office and laboratories are located within the Small Technologies Cluster, a successful and thriving environment where a number of biotechnology and other high technology businesses have their research and development, commercialisation and manufacturing operations.
Sienna's focus is in creating a portfolio of unique and clinically useful tests for the pathology diagnostics market and clinical diagnostic laboratories worldwide.
In July 2020, the company was acquired by BARD1 Life Sciences.
Contact Details
Company Activity
| NEWS: Tagged in BARD1 raises $15m for cancer detection tests | 23 Jul 2021 |
| NEWS: Tagged in BARD1 soars on cancer tech update | 15 Feb 2021 |
| NEW ROLE: Tony Di Pietro, Chief Financial Officer, Company Secretary | 03 Aug 2020 |
| NEW ROLE: Tony Di Pietro, Executive Director | 03 Aug 2020 |
| NEW ROLE: Carl Stubbings, Managing Director, Chief Executive | 03 Aug 2020 |
| NEW ROLE: Carl Stubbings, Non-Executive Director | 03 Aug 2020 |
| NEW ROLE: Helen Fisher, Non-Executive Director | 03 Aug 2020 |
| NEW ROLE: Geoffrey Cumming, Non-Executive Chair | 03 Aug 2020 |
| NEW ROLE: Peter French, Strategic Technology Advisor | 24 Jul 2020 |
